Mr Paras Singh

Job title

Consultant urologist

Qualifications

MBBS MRCS MD FRCS (Urology)

GMC Number

6094190

Contact details

PA/secretary phone number: 020 7317 7735/020 7794 0500 ext 33068

PA/secretary email address: sheila.ogunbiyi@nhs.net

Related services

Urology

Biography

Mr Paras Singh is a consultant urologist with special interests in benign prostatic disease (medical management and minimally invasive therapy - TURiS), prostate cancer (MRI fusion prostate biopsies, template biopsies and active surveillance), urothelial cancers (endoscopic management of bladder cancer and upper tract cancer) and stone diseases. He is also an investigator in prostate and bladder cancer clinical trials.

Publications

Original articles

  • The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies. Valerio M, Anele C, Bott SR, Charman SC, van der Meulen J, El-Mahallawi H, Emara AM, Freeman A, Jameson C, Hindley RG, Montgomery BS, Singh PB, Ahmed HU, Emberton M. J Urol. 2016 May;195(5):1403-8. PMID: 26741696 
  • Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer. Valerio M, Anele C, Charman SC, van der Meulen J, Freeman A, Jameson C, Singh PB, Emberton M, Ahmed HU. BJU Int. 2016 Sep;118(3):384-90. PMID: 26332050
  • Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Singh PB, Anele C, Dalton E, Barbouti O, Stevens D, Gurung P, Arya M, Jameson C, Freeman A, Emberton M, Ahmed HU. Eur Urol. 2014 Jul;66(1):12-9.  PMID: 24207133
  • Segregation of human prostate tissues classified high-risk (UK) versus low-risk (India) for adenocarcinoma using Fourier-transform infrared or Raman microspectroscopy coupled with discriminant analysis. Patel II, Trevisan J, Singh PB, Nicholson CM, Krishnan RK, Matanhelia SS, Martin FL. Anal Bioanal Chem. 2011 Aug;401(3):969-82. PMID: 21139866
  • Constitutive expression of bioactivating enzymes in normal human prostate suggests a capability to activate pro-carcinogens to DNA-damaging metabolites. Martin FL, Patel II, Sozeri O, Singh PB, Ragavan N, Nicholson CM, Frei E, Meinl W, Glatt H, Phillips DH, Arlt VM. Prostate. 2010 Oct 1;70(14):1586-99. PMID: 20687231
  • SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, Berney DM, Møller H, Reuter VE, Scardino P, Cuzick J, Ragavan N, Singh PB, Martin FL, Butler CM, Cooper CS, Swain A; Transatlantic Prostate Group. Cancer Res. 2010 Feb 1;70(3):979-87. PMID: 20103652
  • Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. Singh PB, Ragavan N, Ashton KM, Basu P, Nadeem SM, Nicholson CM, Krishna RK, Matanhelia SS, Martin FL. Asian J Androl. 2010 Mar;12(2):203-14. PMID: 19935673
  • Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience. Singh PB, Nicholson CM, Ragavan N, Blades RA, Martin FL, Matanhelia SS. BMC Urol. 2009 May 27;9:3. PMID: 19473479
  • Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate. John K, Ragavan N, Pratt MM, Singh PB, Al-Buheissi S, Matanhelia SS, Phillips DH, Poirier MC, Martin FL. Prostate. 2009 Apr 1;69(5):505-19. PMID: 19143007
  • Use of tissue ink to maintain identification of individual cores on needle biopsies of the prostate. Singh PB, Saw NK, Haq A, Blades RA, Martin FL, Matanhelia SS, Nicholson CM. J Clin Pathol. 2008 Sep;61(9):1055-7. PMID: 18641411
  • A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Singh PB, Matanhelia SS, Martin FL. Eur J Cancer. 2008 May;44(7):928-36. 
  • An integrated laparoscopic simulator (i-Sim) to develop surgical skills outside the operating theatre: a novel means to improve training facilities in the UK. Singh PB, Saw NK, Mokete M, Martin FL, Matanhelia SS. Int J Surg. 2008 Feb;6(1):64-70. PMID: 17804310

Letters

  • Time to Rethink PSA Screening. Singh PB, Ahmed HU, Simmons L, Freeman A, Emberton M. Arch Intern Med. 2011 Mar 28;171(6):595. PMID: 21444857
  • Active Surveillance: Is There a Need for Better Risk Stratification at the Outset? Singh PB, Ahmed HU, Emberton M. J Clin Oncol. 2010. PMID: 20697073
  • The risk of prostate cancer amongst South Asian men in southern England: the PROCESS cohort study. Singh PB, Ragavan N, Martin FL. BJU Int. 2009 Feb;103(4):553. PMID: 19187348

Book chapter

  • Prostate Biopsy. In Prostate Cancer: A Comprehensive Perspective (2013)